Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer

NCT04938583 is registered in ClinicalTrials.gov with CanariaBio Inc. as lead sponsor.

NCT NCT04938583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04938583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer
Lead sponsor
CanariaBio Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 17, 2021
Completion date
August 31, 2026
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer by figo stage, ovarian cancer stage iii, ovarian cancer stage iv